NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

TerminatedN/A

Sponsor: Pfizer

Conditions: Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors, Urothelial Carcinoma

Interventions: Avelumab first-line maintenance

Countries: Canada

The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer. This study is including participants who: * Participated in the Canadian avelumab patient support program * Have been diagnosed with advanced bladder cancer * Have been treated with platinum-based chemotherapy without their disease progressing All participants in this study have previously received avelumab first-line maintenance for the treatment of their advanced bladder cancer. Pfizer will examine the experiences of people receiving the study medicine. This will help determine the efficacy and safety of the study medicine for the treatment of bladder cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Enrolled in the Canadian avelumab1LM Patient support program (PSP)
* Histologically confirmed diagnosis of stage IV LA/mUC
* No evidence of disease progression following first-line platinum-based chemotherapy
* Receipt of avelumab1LM following 1L platinum-based chemotherapy
* Received the last dose of chemotherapy no more than 10 weeks before entering the PSP
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* ≥6 months of follow-up from initiation of AVE 1LM therapy until study end date, unless the patient has died, with known date of death.

Exclusion Criteria:

* Diagnosed with LA/mUC and enrolled in the PSP, but did not receive avelumab
* Pregnancy at index date
* Participation in an interventional clinical trial at any point during the study period

The index date will be considered as the initiation of index therapy. The index therapy will be considered as the avelumab 1LM treatment after 1L platinum-based chemotherapy.

Locations (1)

Mississauga, Ontario, Canada